Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $9.91, but opened at $10.77. Capricor Therapeutics shares last traded at $10.2510, with a volume of 1,487,566 shares traded.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor shares rose after an August FDA update, suggesting investors viewed the latest regulatory communication as somewhat less negative or more constructive than previously feared. The FDA’s ongoing review of Deramiocel remains the primary potential catalyst for CAPR. Capricor Therapeutics shares rise following August FDA update

Analyst Ratings Changes

CAPR has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $29.15.

Capricor Therapeutics Trading Up 3.1%

The business has a 50-day moving average of $14.07 and a 200 day moving average of $24.19. The firm has a market capitalization of $593.90 million, a P/E ratio of -4.18 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). As a group, research analysts forecast that Capricor Therapeutics, Inc. will post -1.72 EPS for the current year.

Insider Buying and Selling at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 25,000 shares of company stock valued at $759,158 in the last 90 days. 9.20% of the stock is owned by company insiders.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently made changes to their positions in the company. Montanova Capital LLC lifted its position in shares of Capricor Therapeutics by 7.2% during the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after buying an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $49,062,000. Finally, California State Teachers Retirement System grew its holdings in shares of Capricor Therapeutics by 2,261.8% in the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock valued at $36,806,000 after acquiring an additional 1,463,762 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.